{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '15.', 'LIST OF REFERENCES', '1. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human', 'phase I study of selinexor, a selective inhibitor of nuclear export, in patients with', 'advanced solid tumors. J Clin Oncol. 2016.', '2. ACS (American Cancer Society). Key statistics for multiple myeloma. 28 February 2018.', 'Available from: http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-', 'myeloma-key-statistics.', '3. Alexander TB, Lacayo NJ, Choi JK, et al. Phase I study of selinexor, a selective inhibitor', 'of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or', 'refractory acute leukemia. J Clin Oncol. 2016;34(34):4094-101.', '4. Argueta C, Kashayp T, Klebanov B, Unger TJ, Guo C, Harrington S, et al. Selinexor', 'synergizes with dexamethasone to repress mTORC1 signaling and induce multiple', 'myeloma cell death. Oncotarget. 2018; 9 (39):25529-44.', '5.', 'Bahlis N, Chen C, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, et al. Selinexor', 'in combination with weekly low dose bortezomib and dexamethasone (SVd) induces a', 'high response rate with durable responses in patients with refractory multiple myeloma', '(MM). 2017 ASH Annual Meeting, December 9 - December 12, 2016, Atlanta, Georgia.', '6. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in', 'multiple myeloma patients. Blood. 2010;116(23):4745-53.', '7.', 'Crochiere ML, Baloglu E, Klebanov B, et al. A method for quantification of exportin-1', '(XPO1) occupancy by selective inhibitor of nuclear export (SINE) compounds.', 'Oncotarget. 2016;7(2):1863-77.', '8.', 'Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential trials.', 'Biometrics. 1999; 55:853-857.', '9. Dexamethasone Prescribing Information. Dexamethasone Prescribing Information, USA.', 'Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cca2c160', '9188-48e8-9505-49a52388dcb7.', '10. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus', 'bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma', '(ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol.', '2016;17(1):27-38.', '11. Dubois D, Dubois E. A formula to estimate the approximate surface area if height and', 'weights be known. Arch Intern Medicine. 1916;17:863-71.', '12. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for', 'multiple myeloma. Leukemia. 2006;20(9): 1467-73.', '13. Fridericia L. Die Systolendauer im elektrokardiogramm bei normalen menschen und bei', 'herzkranken. [The duration of systole in the electrocardiogram of normal subjects and of', 'patients with heart disease.]. Acta Medica Scandinavica. 1920;53:469-86.', 'Confidential', 'Page 108', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '14. Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, et al. Next-', 'generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in', 'hematological malignancies. Leukemia. 2016;30:2364-72.', '15. Jakubowiak A, Jasielec J, Rosenbaum C. Final results of phase 1 MMRC trial of', 'selinexor, carfilzomib, and dexamethasone in relapsed/relapsed/refractory multiple', 'myeloma. 2016 ASH Annual Meeting, Dec 03-06 2016, San Diego, CA.2016.', '16. Kandarpa M, Alonge MM, Jasielec J, et al. Effects of inhibition Of XPO1/CRM1- -', 'dependent nuclear export by eelinexor (KPT-330), alone and in combination with', 'carfilzomib (CFZ), on apoptosis and autophagy in multiple myeloma (MM). Blood.', '2013;122(21):279', '17. Kashyap T, Argueta C, Aboukameel A, et al. Selinexor, a Selective Inhibitor of Nuclear', 'Export (SINE) compound, acts through NF-kappaB deactivation and combines with', 'proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016.', '18. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group', 'consensus criteria for response and minimal residual disease assessment in multiple', 'myeloma. The Lancet Oncology. 2016;17(8):e328-46.', '19. Lan K, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika.', '1983;70:659-63.', '20. Mateos MV, Bringhen S, Richardson PG, et al. Bortezomib cumulative dose, efficacy,', 'and tolerability with three different bortezomib-melphalan-prednisone regimens in', 'previously untreated myeloma patients ineligible for high-dose therapy. Haematologica.', '2014;99(6):1114-22', '21. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous', 'administration of bortezomib in patients with relapsed multiple myeloma: a randomised,', 'phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.', '22. Moreau P, Karamanesht, II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic', 'and covariate analysis of subcutaneous versus intravenous administration of bortezomib', 'in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823-9.', '23. Mosteller RD. Simplified calculation of body-surface area. N. Eng. J. Med.', '1987;317(17):1098.', '24. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in', 'Oncology (NCCN Guidelines): Fatigue, Palliative Care, and Antiemesis. Available from:', 'ttp://www.nccn.org/professionals/physician_gls/f_guidelines.asp', '25. NCT01568866. Phase 3 study with carfilzomib and dexamethasone versus bortezomib', 'and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR) - sponsored', 'by Onyx. Available from: https://clinicaltrials.gov/ct2/show/NCT01568866.', '26. NCT01734928. Safety and efficacy of pomalidomide, bortezomib and low-dose', 'dexamethasone in subjects with relapsed or refractory multiple myeloma (OPTIMISMM)', '-sponsored by Celgene Corporation. Available from:', 'ttps://clinicaltrials.gov/ct2/show/NCT01734928', 'Confidential', 'Page 109', 'Version 4.0']\n\n###\n\n", "completion": "END"}